Lung Cancer
How I will treat my next patient
Chemo-free neoadjuvant approaches emerge in NSCLC and breast cancer
Dr. Alan P. Lyss breaks down new data presented on immune checkpoint inhibitors in NSCLC and trastuzumab emtansine for HER2-positive breast cancer...
News
FDA approves pembrolizumab for advanced SCLC
The approval was based on an overall response rate of 19% in two nonrandomized trials.
From the Journals
Neoadjuvant-adjuvant erlotinib shows promise in locally advanced NSCLC
The EMERGING trial failed to meet its primary endpoint of higher OR but did meet the secondary endpoint of longer PFS.
Conference Coverage
Adding ipilimumab to nivolumab provides no benefit in SCC trial
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
Conference Coverage
Nivo/ipi shrinks early NSCLC before surgery
CHICAGO – Among patients who went on to resection, 44% of those who had received neoadjuvant nivolumab and ipilimumab had a major pathological...
How I will treat my next patient
NSCLC: Local consolidative therapy in oligometastatic disease and immunotherapy in EGFR mutations
Dr. Alan P. Lyss looks at two recent reports about treatment in non–small cell lung cancer.
Conference Coverage
Repotrectinib highly active in ROS1-positive lung cancer
Pivotal phase 2 portion of study to commence later this year.
From the Journals
Checkpoint inhibitor rechallenge is possible for select patients
Rechallenge resulted in the recurrence of a grade 2 or higher immune-related adverse event (irAE) in 55% of rechallenged patients, but no deaths...
Conference Coverage
Pembrolizumab improves 5-year OS in advanced NSCLC
CHICAGO – In a phase 1b trial of pembrolizumab, the 5-year OS rate was 23.2% in treatment-naive patients and 15.5% in previously treated patients...
From the Journals
Low-dose CT lung cancer screening nets payoff in community setting too
A survey of 165 lung cancer screening centers suggests low-dose CT screening is being effectively implemented in community practices, replicating...